Have you recently diagnosed lymphoma in a dog? Has the client declined chemotherapy or is undecided? 

PharmAust is enrolling dogs with B-cell lymphoma in a clinical trial investigating a novel oral cancer medication.

All diagnostic and treatment costs are covered in this study, with the initial consultation cost borne by the client. Participants are enrolled in the trial for a month.

Phase I & II clinical trials have shown that this drug is safe and leads to clinical benefit in dogs with treatment-naive B-cell lymphoma. Post-trial follow-ups suggest that the combination with prednisolone may be capable of at least double the life expectancy of pet dogs with B-cell lymphoma compared to treatment with prednisolone alone.

PharmAust and participating vets are currently in the process of fine-tuning the optimal dosage & looking forward to moving forward with a Phase III clinical trial to further test this drug alone & in combination with prednisolone.

Dogs may be eligible for the trial if they:

• Have not been pre-treated with chemotherapy or prednisolone

• Have B-cell multicentric lymphoma 

• Are well enough to survive the duration of the trial (4 weeks)

• Weigh more than 8 kg

Interested owners can contact Kim Agnew from PharmAust: kim@kapconsulting.com.au

For testimonials from pet owners, please visit: https://www.pharmaust.com/veterinary-trial-testimonials/